Skip to main content

Table.5 Summary of solicited and unsolicited adverse reactions occurred within 28 days during the study period

From: Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

Adverse reaction* 0–14 group
(n = 270)
0–21 group
(n = 270)
0–28 group
(n = 269)
P
Solicited adverse reactions within 0–7 days    
 Local reactions 7 (2.6) 9 (3.3) 4 (1.5) 0.418
  Pain 4 (1.5) 7 (2.6) 2 (0.7) 0.263
  Swelling 2 (0.7) 0 (0.0) 2 (0.7) 0.479
  Pruritus 1 (0.4) 2 (0.7) 0 (0.0) 0.777
 Systemic reactions 1 (0.4) 2 (0.7) 3 (1.1) 0.545
  Diarrhea 0 (0.0) 1 (0.4) 1 (0.4) 0.777
  Fatigue 1 (0.4) 1 (0.4) 2 (0.7) 0.702
Unsolicited adverse reactions within 8–28 days    
 Local reactions 1 (0.4) 1 (0.4) 1(0.4) 1.000
  Rash 1 (0.4) 1 (0.4) 1(0.4) 1.000
 Systemic reactions 2 (0.7) 1 (0.4) 2(0.7) 0.876
  Cough 1 (0.4) 1 (0.4) 1(0.4) 1.000
  Headache 1 (0.4) 0 (0.0) 1(0.4) 0.777
  1. Results expressed as n (%)
  2. *Adverse reaction data only list the occurrence of this symptom